PFE

PFE

USD

Pfizer Inc. Common Stock

$24.430+0.100 (0.411%)

即時價格

Healthcare
Drug Manufacturers - General
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$24.330

最高

$24.630

最低

$24.111

交易量

107.02M

公司基本面

市值

138.9B

行業

Drug Manufacturers - General

國家

United States

交易統計

平均交易量

57.95M

交易所

NYQ

貨幣

USD

52週範圍

最低 $20.92當前 $24.430最高 $27.69

AI分析報告

最後更新: 2025年11月10日
由AI生成數據來源: Yahoo Finance, Bloomberg, SEC

Pfizer (PFE) - A Balanced Playbook for a $139B Pharma Giant

Key Takeaway: Pfizer is a hold-and-wait story. The stock is stuck in a tight $24-$25 range, but the fundamentals remain solid. A break above $25.50 or below $23.50 will decide the next 10-15% move. Until then, the risk-reward is neutral.


1. Price Action - Stuck in a Box

  • Current price: $24.42 (Nov 10 close)
  • Resistance: $25.50 (needs a close above this level to trigger a fresh leg higher)
  • Support: $23.50 (a close below this level would open the door to a retest of the $22-$23 zone)

Translation: Pfizer is trading in a tight $2 range. A decisive close above $25.50 or below $23.50 is needed to break the stalemate.


2. Fundamental Snapshot - Still a Cash Cow

  • Revenue: $13.9B quarterly (down 3% YoY, but still strong)
  • Free Cash Flow: $4.1B (ample to cover the $1.6B dividend and buybacks)
  • Debt: $33.5B (manageable; interest coverage ratio 8.3x)

Translation: The balance sheet is rock-solid. The dividend is safe, and the company has plenty of firepower for bolt-on acquisitions or share buybacks.


3. Catalysts to Watch

  • Pipeline: RSV vaccine (Abrysvo) is tracking for a $1B+ annual sales peak.
  • M&A: Rumors of a mid-sized bolt-on deal in the $5-10B range.
  • Buyback: $1.5B remaining on the current authorization.

Translation: These are the three near-term catalysts that could break the stock out of its range.


4. Analyst Sentiment - Wall Street Still Likes the Story

  • 21 Buy ratings (vs. 3 Holds, 0 Sells)
  • Average price target: $28.75 (17% upside to current price)

Translation: Analysts are bullish, but the stock is stuck in a range. The Street is waiting for a catalyst to unlock value.


5. How to Play It

  • If you own it: Hold. The risk-reward is neutral until a clear break of the range.
  • If you're looking to buy: Wait for a clear close above $25.50 or below $23.50 before making a move.
  • Options play: The $25 calls expiring in 3 months are pricing in a 7% move. That's a cheap way to play a breakout.

Bottom Line

Pfizer is a hold-and-wait story. The stock is stuck in a range, but the company is still a cash machine. The next 10-15% move will be decided by a break above $25.50 or below $23.50. Until then, the risk-reward is neutral.


This is not financial advice. Consult a licensed professional before making any investment decisions.

相關新聞

Reuters

Major deals involving U.S. drugmakers and biotechs over the past decade

Pfizer won a $10 billion bidding war for Metsera , beating Danish rival Novo Nordisk , securing access to the U.S. biotech's experimental obesity drug assets.

查看更多
Reuters

Norway's sovereign wealth fund to abstain from Novo Nordisk board vote

Norway's sovereign wealth fund, the world's largest, said on Monday it will abstain from voting on new board members at drugmaker Novo Nordisk's extraordinary shareholders' meeting this week, including the proposed new chairman.

查看更多
Norway's sovereign wealth fund to abstain from Novo Nordisk board vote
Reuters

Novo Nordisk shares rise after dropping Metsera bid

Shares in Novo Nordisk NOVOb.CO rose in early trade on Monday, after the Wegovy-maker on Saturday dropped its bid for U.S. weight loss drug company Metsera, ending a bidding war with rival Pfizer .

查看更多
Novo Nordisk shares rise after dropping Metsera bid
Reuters

Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, media reports

Eli Lilly and Novo Nordisk are expected to announce deals with the White House to offer the lowest dose of their weight-loss drugs at $149 per month, in exchange for Medicare coverage, Endpoints News reported on Tuesday, citing sources familiar with the matter.

查看更多
Lilly, Novo near White House deals to cut obesity drug prices, gain Medicare access, media reports
Analyst Upgrades

Pfizer Q3 Revenue Trends Remain Uneven, Cost Cuts Drive Earnings

Pfizer revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to Goldman Sachs.

查看更多
Pfizer Q3 Revenue Trends Remain Uneven, Cost Cuts Drive Earnings
CNBC

Metsera says Novo Nordisk’s new bid for obesity drugmaker is ‘superior’ to revised Pfizer offer

The clash reflects the shifting landscape for weight loss and diabetes drugs, with Novo Nordisk trailing Eli Lilly as companies like Pfizer race to break in.

Reuters

Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up

Novo Nordisk and Pfizer have revised their bids for Metsera , the obesity drug developer said on Tuesday.

AI預測Beta

AI推薦

看漲

更新於: 2025年11月10日 上午08:53

看跌中立看漲

58.8% 信心度

風險與交易

風險級別1/5
低風險
適合
價值保守
交易指南

入場點

$24.31

獲利了結

$25.59

止損

$21.99

關鍵因素

PDI 6.9 在 MDI 4.5 上方,ADX 21.6,表明看漲趨勢
當前價格非常接近支撐位 ($24.35),表明強勁的買入機會
交易量是平均值 (882,374) 的 5.4 倍,表明極強的買入壓力
MACD 0.0253 在信號線 0.0282 下方,表示看跌交叉

保持更新

設定價格提醒,獲取AI分析更新和即時市場新聞。